^
    Back
    Association details:
    Biomarker:CHEK2 mutation
    Cancer:Prostate Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    BMJ Case Rep
    Title:

    Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation

    Published date:
    01/18/2023
    Excerpt:
    We present the case of a patient with germline CHEK2-mutated metastatic castration-resistant prostate cancer (mCRPC) who responded to bipolar androgen therapy (BAT) combined with pembrolizumab after progressing through multiple lines of therapy.
    DOI:
    10.1136/bcr-2022-251320